	US 11,911,375 B2
	Solid oral nicotine formulation
Kent Albin Nielsen, Brande (DK); and Jessie Poulsen, Odense SV (DK)
Assigned to FERTIN PHARMA A/S, Vejle (DK)
Filed by Fertin Pharma A/S, Vejle (DK)
Filed on Nov. 16, 2020, as Appl. No. 17/098,550.
Prior Publication US 2022/0152013 A1, May 19, 2022
Int. Cl. A61K 31/465 (2006.01); A61K 9/68 (2006.01); A61K 9/20 (2006.01); A61K 47/02 (2006.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/44 (2017.01)

CPC A61K 31/465 (2013.01) [A61K 9/0058 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2068 (2013.01); A61K 47/02 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/44 (2013.01)]

17 Claims

1. A solid oral nicotine formulation comprising

a nicotine-ion exchange resin combination,

and a salt comprising inorganic divalent cations,

wherein the salt is present as a separate component,

wherein the solid oral nicotine formulation comprises divalent cations in molar ratio of 0.1 to 5 relative to the amount of nicotine in the nicotine-ion exchange resin combination,

wherein the solid oral nicotine formulation is selected from the group consisting of a lozenge, a chewable tablet, and a chewing gum,

wherein the ion exchange resin comprises a copolymer of methacrylic acid and divinylbenzene, said copolymer containing carboxylic functional groups, and

wherein the salt is selected from the group consisting of calcium chloride and magnesium chloride, or combinations thereof.